ClinicalTrials.gg
CompletedNCT02079636Updated Sep 11, 2020Results posted

A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)

A Phase 1 interventional study of Abemaciclib and Pemetrexed in Carcinoma, Non-small Cell Lung, sponsored by Eli Lilly and Company. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-11.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
142
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 9 under way, 2 of them phase 3. Ramucirumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
10th of 24
142 · median 74
Started
2014
with 1 other
Phase 1
4 of 24
none open now
Registered
5th of 24
by date
Lead sponsor
10 of 24
Eli Lilly and Company

Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, this one is the 10th largest by enrollment, is one of 2 that started in 2014, is one of 4 in phase 1, and was the 5th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ramucirumab

Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and tolerability of abemaciclib in combination with another anti-cancer drug in participants with NSCLC that is advanced or has spread to other parts of the body (stage IV). The study will also investigate how the body processes the combination treatment and how the study drug affects the body. The study will also collect disease-related symptoms and participant-reported pain related to NSCLC.

03

Conditions studied

  • Carcinoma, Non-small Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For all Parts: The participant must have stage IV non-small cell lung cancer (NSCLC).
  • For Part A (abemaciclib + pemetrexed): Non-squamous subtypes only. The participant must have received at least one but no more than three prior therapies for advanced/ NSCLC.
  • For Part B (abemaciclib + gemcitabine): Any subtype. The participant must have received at least one but not more than three prior therapies for advanced/metastatic NSCLC.
  • For Part C (abemaciclib + ramucirumab): Any subtype. The participant must have received at least two but not more than three prior therapies for advanced/metastatic NSCLC.
  • For Part D (abemaciclib + LY3023414): Any subtype. The participant must have received at least two, but not more than three prior therapies for advanced/metastatic NSCLC. The participant must not have received prior treatment with any phosphoinositide 3-kinase (PI3K) or mammalian target of rapamycin (mTOR) inhibitor.
  • For Part E (abemaciclib + pembrolizumab): Any subtype. The participant must have received at least one but no more than three prior therapies for advanced/metastatic NSCLC.
  • Have either measureable or nonmeasurable disease as defined by the (RECIST v1.1).
  • Have adequate organ function including:

    • Hematologic: (ANC) 1.5 x 109/liter (L), 100 x 109/L, and 8 gram/deciliter (g/dL).
    • Hepatic: 1.5 times (ULN), (ALT) and aspartate transaminase (AST) 3.0 times ULN. For participants with tumor involvement of the liver, AST and ALT equaling ≤5.0 times ULN are acceptable. Alkaline phosphatase ≤5.0 times ULN for participants with tumor involvement of the bone is acceptable.
    • Renal: Serum creatinine 1.5 times ULN.
  • Have a performance status ≤1 on the (ECOG) scale.
  • Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapy (treatment related toxicity resolved to baseline) except for residual alopecia.
  • Male and female participants of must agree to use medically approved precautions during the trial and 3 to 4 months (as appropriate) following last dose of study drug.
  • Have an estimated of ≥12 weeks.
  • Are able to swallow oral medications.

Exclusion criteria

Exclusion Criteria:

  • Have a personal history of any of the following conditions: presyncope or syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Exception: Participants with controlled atrial fibrillation for >30 days prior to study treatment are eligible.
  • Parts A, B, D and E: Have central nervous system (CNS) with development of associated neurological changes 14 days prior to receiving study drug.
  • Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix or breast), unless in complete remission with no therapy for a minimum of 3 years.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 3 to 4 months after the last dose of trial treatment (as appropriate).
  • Have active bacterial, fungal, and/or known viral infection (for example, [HIV] antibodies, surface antigen [HBSAg], or antibodies). Screening is not required for enrollment.
  • Parts A, B, C, and E: Have of > 470 millisecond (msec) on screening (ECG). Part D participants have QTc interval of >450msec on screening ECG.

Additional Exclusion Criteria For Part C

  • History or evidence of cardiovascular risk including any of the following:

    • History of acute coronary syndromes (including myocardial infarction and angina), coronary angioplasty, or stenting within 6 months prior to enrollment.
    • History or evidence of current ≥Class II congestive heart failure as defined by .
    • Treatment hypertension defined as a blood pressure of systolic >140 millimeter of mercury (mmHg) and/or diastolic >90 mmHg which cannot be controlled by antihypertensive therapy.
    • Participants with intracardiac defibrillators.
  • History or evidence of CNS disease. Radiographic screening of all participants without history of is required.
  • Radiographically documented evidence of major vessel invasion or encasement by cancer.
  • Uncontrolled thromboembolic or hemorrhagic disorders.
  • Participants receiving daily treatment with aspirin >325mg/day or other known inhibitors of function.
  • History of gross hemoptysis within 2 months of study entry.
  • Evidence of nonhealing wounds, ulcers, or bone fractures within 28 days prior to study entry.
  • Undergone major surgery within 28 days prior to first dose of study drug or have subcutaneous venous access device placement within 7 days prior to first dose.

Additional Exclusion Criteria For Part D

  • Have insulin-dependent diabetes mellitus or a history of gestational diabetes mellitus.
  • Participants with a type 2 diabetes mellitus are eligible if adequate control of blood glucose level is obtained by oral anti-diabetic agents as documented by (HbA1c) \<7%.
  • History or evidence of cardiovascular risk including any of the following -- History of acute coronary syndromes (including myocardial infarction and angina), coronary angioplasty, or stenting within 6 months prior to enrollment.

Additional Exclusion Criteria for Part E

  • Received prior monoclonal antibody (mAb) within 4 weeks prior to study.
  • Has active disease that has required treatment in the past 2 years.
  • Has history of interstitial lung disease or pneumonitis.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    Abemaciclib + Pemetrexed

    150 milligram (mg) or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 500 milligrams/square meter (mg/m\^2) pemetrexed given intravenously (IV) over approximately 10 minutes on Day 1 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Abemaciclib · Drug: Pemetrexed

  • Experimental
    Abemaciclib + Gemcitabine

    150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 1250 milligram/square meter (mg/m\^2) gemcitabine given intravenously over approximately 30 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Abemaciclib · Drug: Gemcitabine

  • Experimental
    Abemaciclib + Ramucirumab

    150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Day 1 or 8 to 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Abemaciclib · Drug: Ramucirumab

  • Experimental
    Abemaciclib + LY3023414

    100 mg or 150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 100, 150, or 200 mg LY3023414 given orally every 12 hours on Days 1 through 21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Abemaciclib · Drug: LY3023414

  • Experimental
    Abemaciclib + Pembrolizumab

    100 mg or 150 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 200 mg pembrolizumab given intravenously over approximately 30 minutes on day 1 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Abemaciclib · Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLT) or DLT-equivalent in Part A, B, C, D and E

    A DLT defined as adverse event(AE) occurring between Day 1 and Day 21 of Cycle 1 that was considered at least possibly related to either abemaciclib or the combination therapy and fulfilled a criteria selected (using the National Cancer Institute Common Terminology Criteria for Adverse Events,version 4.0 \[NCI-CTCAE v 4.0\] \[NCI 2009\]):Grade(Gr)≥3 nonhematological toxicity,Gr4 thrombocytopenia lasting at least 5 days and/or complicated with bleeding,Gr≥3 febrile neutropenia(ntr) and for Part D participants (pts): Gr3 hyperglycemia (fasting) of \<5 days, Gr3 hypertriglyceridemia or hyperlipidemia without optimal treatment.A DLT-equivalent defined as AE that would have met the criteria for DLT if it had occurred during Cycle 1 for pts enrolled in dose-escalation phase,but that occurs between 1)Day 1 and Day 21 of Cycle 2 and beyond for a participant enrolled in dose-escalation phase 2) at any time for a participant in dose-expansion phase.

    Time frame: Baseline through study completion (Up To 15 Months)

Secondary outcomes

  1. Number of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) in Part A, B, C, D and E

    ORR is the best response of CR or PR as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of not-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.

    Time frame: Baseline through study completion (Up To 15 Months)

  2. Progression Free Survival Time in Part A, B, C, D and E

    Progression free survival (PFS) defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. PFS time was summarized using Kaplan-Meier estimates.

    Time frame: Date of first dose until first documented progression or death (Up To 15 Months)

  3. Change From Baseline in MD Anderson Symptom Inventory Scale-Lung Cancer (MDASI-LC) in Part A, B, C, D and E

    The MDASI-LC is a self-reported lung cancer instrument included 22 items covered by one of the following dimensions: Mean core symptom severity (Core items 1-13: pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sad, vomiting, numbness/tingling), Lung cancer symptoms (3 items: coughing, constipation, sore throat), Mean symptom severity (13 core items plus 3 lung items) and Interference with mood or functional status (6 items: general activity, mood, work, relations with other people, walking, enjoyment of life). The mean of all symptom subscale items was calculated where 0 equals "not present" and 10 equals "as bad as you can imagine." A change from baseline with negative values indicate improvement, positive values indicate worsening.

    Time frame: Baseline, through study completion (Up To 15 Months)

  4. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib on Day 1 and at Steady State (Cycle 2 Day 1) in Part A , B, C, D and E

    Cmax of Abemaciclib on day 1 and at steady State (Cycle 2 Day 1) Part A , B, C, D and E was evaluated.

    Time frame: Cycle 1 Day 1 (C1D1) pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; Cycle 2 Day 1 (C2D1) pre-dose and 1, 2, 4, 6, 8, 10 h post-dose

  5. Pharmacokinetics: Maximum Concentration (Cmax) of Pemetrexed at Steady State in Part A

    Cmax of pemetrexed at steady state in Part A was evaluated.

    Time frame: C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose

  6. PK: Dose-normalized Maximum Concentration (Cmax) of Active Gemcitabine Metabolite: 2',2'-Difluorodeoxyuridine (dFdU) on Day 1 and at Steady State (Cycle 2 Day 1) in Part B

    Cmax of active gemcitabine metabolite (dFdU) on day 1 and at steady state (Cycle 2 Day 1) dose-normalized to 1250 mg/m\^2 in Part B was evaluated.

    Time frame: C1D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose

  7. PK: Maximum Concentration (Cmax) of Ramucirumab at 1 Hour Post-End-of-Infusion in Part C

    Cmax of ramucirumab at 1 hour post-end-of-Infusion in Part C was evaluated.

    Time frame: C1D1 and C2D1: 1 hour post-end-of-infusion

  8. PK: Maximum Concentration (Cmax) of LY3023414 in Part D

    Cmax of LY3023414 in Part D was evaluated.

    Time frame: C1D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose

  9. PK: Area Under the Concentration Curve (AUC) of Abemaciclib in Part A, B, C, D and E

    Area under the concentration time curve from zero to 8 hours AUC(0-8h) of abemaciclib in Part A, B, C, D and E was evaluated.

    Time frame: C1D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose

  10. PK: Area Under the Concentration Curve (AUC) of Pemetrexed at Steady State in Part A

    Area under the plasma concentration versus time curve from time zero to infinity (AUC\[0-∞\]) of Pemetrexed in Part A was evaluated.

    Time frame: C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose

  11. PK: Area Under the Concentration Curve (AUC) of Active Gemcitabine Metabolite: 2',2'-Difluorodeoxyuridine (dFdU) on Day 1 and at Steady State (Cycle 2 Day 1) in Part B

    Area under the plasma concentration time curve from time zero to 12 hours (AUC\[0-12h\]) of active gemcitabine metabolite (dFdU) in Part B was evaluated

    Time frame: C1D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose

  12. PK: Area Under the Concentration Curve (AUC) of LY3023414 in Part D

    Area under the plasma concentration versus time curve from time zero to infinity (AUC) of LY3023414 in Part D was evaluated. For Day 1, AUC is defined as AUC from time zero to infinity (AUC\[0-∞\]), for steady state, AUC is defined as AUC from time zero to the end of the dosing interval, tau (AUC\[0-tau \])

    Time frame: C1D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose

07

Results

Posted Sep 11, 2020

Participant flow

Participant flow — Overall Study
MilestonePart A: 150 Milligram(mg) Abemaciclib + 500 mg/m^2 PemetrexedPart A: 200 mg Abemaciclib + 500 mg/m^2 PemetrexedPart B: 150 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart C: 150 mg Abemaciclib + 10mg/kg Ramucirumab Day 1Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8Part D: 100 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 150 mg LY3023414Part D: 200 mg Abemaciclib + 150 mg LY3023414Part D: 150 mg Abemaciclib + 200 mg LY3023414Part E: 100 mg Abemaciclib + 200 mg PembrolizumabPart E: 150 mg Abemaciclib + 200 mg Pembrolizumab
Started815321419124391068317
Received at least one dose of study drug815321419124391068317
Completed5133921311336845312
Not completed3201226110322305
Withdrew: Death210512100001102
Withdrew: Adverse event110112000000000
Withdrew: Progressive disease000200000000100
Withdrew: Withdrawal by subject000401000211102
Withdrew: Physician decision000001000110001
Withdrew: Lost to follow-up000000010000000

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities (DLT) or DLT-equivalent in Part A, B, C, D and E

A DLT defined as adverse event(AE) occurring between Day 1 and Day 21 of Cycle 1 that was considered at least possibly related to either abemaciclib or the combination therapy and fulfilled a criteria selected (using the National Cancer Institute Common Terminology Criteria for Adverse Events,version 4.0 \[NCI-CTCAE v 4.0\] \[NCI 2009\]):Grade(Gr)≥3 nonhematological toxicity,Gr4 thrombocytopenia lasting at least 5 days and/or complicated with bleeding,Gr≥3 febrile neutropenia(ntr) and for Part D participants (pts): Gr3 hyperglycemia (fasting) of \<5 days, Gr3 hypertriglyceridemia or hyperlipidemia without optimal treatment.A DLT-equivalent defined as AE that would have met the criteria for DLT if it had occurred during Cycle 1 for pts enrolled in dose-escalation phase,but that occurs between 1)Day 1 and Day 21 of Cycle 2 and beyond for a participant enrolled in dose-escalation phase 2) at any time for a participant in dose-expansion phase.

Time frame:
Baseline through study completion (Up To 15 Months)
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities (DLT) or DLT-equivalent in Part A, B, C, D and E
ParticipantsPart A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 PemetrexedPart A: 200 mg Abemaciclib + 500 mg/m^2 PemetrexedPart B: 150 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart C:150 mg Abemaciclib+10 mg/kg Ramucirumab Day 1Part C: 200 mg Abemaciclib + 10 mg/kg Ramucirumab Day 1Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8Part D: 100 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 150 mg LY3023414Part D: 200 mg Abemaciclib + 150 mg LY3023414Part D: 150 mg Abemaciclib + 200 mg LY3023414Part E: 100 mg Abemaciclib + 200 mg PembrolizumabPart E: 150 mg Abemaciclib + 200 mg Pembrolizumab
Number of Participants With Dose-Limiting Toxicities (DLT) or DLT-equivalent in Part A, B, C, D and E140514131111200
SecondaryNumber of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) in Part A, B, C, D and E

ORR is the best response of CR or PR as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of not-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.

Time frame:
Baseline through study completion (Up To 15 Months)
Reported as:
Count of participants · Participants
Number of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) in Part A, B, C, D and E
ParticipantsPart A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 PemetrexedPart A: 200 mg Abemaciclib + 500 mg/m^2 PemetrexedPart B: 150 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart C:150 mg Abemaciclib+10mg/kg Ramucirumab Day1Part C: 200 mg Abemaciclib + 10 mg/kg Ramucirumab Day 1Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8Part D: 100 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 150 mg LY3023414Part D: 200 mg Abemaciclib + 150 mg LY3023414Part D: 150 mg Abemaciclib + 200 mg LY3023414Part E: 100 mg Abemaciclib + 200 mg PembrolizumabPart E: 150 mg Abemaciclib + 200 mg Pembrolizumab
Number of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) in Part A, B, C, D and E010111000010002
SecondaryProgression Free Survival Time in Part A, B, C, D and E

Progression free survival (PFS) defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. PFS time was summarized using Kaplan-Meier estimates.

Time frame:
Date of first dose until first documented progression or death (Up To 15 Months)
Reported as:
Median · Months
Progression Free Survival Time in Part A, B, C, D and E
MonthsPart A:Abemaciclib + 500 mg/m^2 PemetrexedPart B: Abemaciclib + 1250 mg/m^2 GemcitabinePart C:Abemaciclib+ 8/10mg/kg Ramucirumab Day1/8Part D: Abemaciclib + 100 mg/150 mg/ 200 mg LY3023414Part E: 100 mg/150 mg Abemaciclib + 200 mg Pembrolizumab
Progression Free Survival Time in Part A, B, C, D and E5.55 (1.81 to 22.47)1.58 (1.18 to 2.46)4.83 (1.61 to 7.16)1.87 (1.41 to 5.32)4.11 (3.02 to NA)
SecondaryChange From Baseline in MD Anderson Symptom Inventory Scale-Lung Cancer (MDASI-LC) in Part A, B, C, D and E

The MDASI-LC is a self-reported lung cancer instrument included 22 items covered by one of the following dimensions: Mean core symptom severity (Core items 1-13: pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sad, vomiting, numbness/tingling), Lung cancer symptoms (3 items: coughing, constipation, sore throat), Mean symptom severity (13 core items plus 3 lung items) and Interference with mood or functional status (6 items: general activity, mood, work, relations with other people, walking, enjoyment of life). The mean of all symptom subscale items was calculated where 0 equals "not present" and 10 equals "as bad as you can imagine." A change from baseline with negative values indicate improvement, positive values indicate worsening.

Time frame:
Baseline, through study completion (Up To 15 Months)
Reported as:
Mean · units on a scale
Change From Baseline in MD Anderson Symptom Inventory Scale-Lung Cancer (MDASI-LC) in Part A, B, C, D and E
units on a scalePart A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 PemetrexedPart A: 200 mg Abemaciclib + 500 mg/m^2 PemetrexedPart B: 150 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart C:150 mg Abemaciclib+10mg/kg Ramucirumab Day1Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8Part D: 100 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 150 mg LY3023414Part D: 200 mg Abemaciclib + 150 mg LY3023414Part D: 150 mg Abemaciclib + 200 mg LY3023414Part E: 100 mg Abemaciclib + 200 mg PembrolizumabPart E: 150 mg Abemaciclib + 200 mg Pembrolizumab
Mean core symptom severity-0.16 (-1.46 to 0.31)0.89 (-0.96 to 2.24)-0.54 (-0.54 to -0.54)-0.08 (-1.54 to 1.08)-0.35 (-2.47 to 1.77)0.61 (-1.04 to 2.70)-0.64 (-1.54 to 1.23)-1.39 (-2.31 to -0.46)0.61 (-1.85 to 2.15)1.89 (1.00 to 3.85)1.60 (-1.15 to 2.77)-0.80 (-2.93 to 0.38)0.28 (-1.62 to 2.18)0.91 (0.19 to 1.93)0.88 (0.47 to 2.08)
Mean symptom severity-0.05 (-1.43 to 0.68)0.83 (-0.86 to 1.82)-0.44 (-0.44 to -0.44)-0.03 (-1.44 to 1.19)-0.41 (-2.31 to 1.50)0.72 (-0.88 to 2.41)-0.61 (-1.25 to 1.06)-1.01 (-2.13 to 0.12)0.64 (-1.63 to 1.94)1.86 (1.50 to 3.62)1.60 (-0.94 to 2.88)-0.73 (-2.82 to 0.37)0.19 (-1.35 to 1.73)0.99 (0.59 to 1.69)0.75 (0.56 to 1.94)
Mean lung cancer symptom1.22 (-1.00 to 3.33)0.71 (-1.00 to 1.00)1.67 (1.67 to 1.67)0.19 (-1.00 to 1.00)-0.67 (-1.67 to 0.33)1.13 (-1.00 to 2.00)-0.78 (-3.00 to 0.67)3.01 (2.67 to 3.34)0.78 (-0.67 to 2.00)1.40 (-0.34 to 2.66)2.19 (0.67 to 3.33)-0.44 (-2.33 to 1.34)0.67 (-1.00 to 2.34)1.67 (0.67 to 2.33)0.23 (-1.00 to 1.67)
Mean interference severity2.32 (1.50 to 4.20)0.49 (-3.00 to 3.59)0.00 (0.00 to 0.00)0.95 (-0.51 to 4.76)-1.33 (-3.83 to 1.17)0.15 (-3.00 to 3.16)-1.00 (-5.16 to 1.33)-3.08 (-4.50 to -1.66)0.72 (-1.17 to 3.50)1.47 (0.17 to 1.67)1.81 (-0.83 to 5.17)-0.22 (-3.17 to 2.17)-0.38 (-4.25 to 3.50)1.44 (0.33 to 2.83)1.00 (-1.67 to 2.84)
SecondaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib on Day 1 and at Steady State (Cycle 2 Day 1) in Part A , B, C, D and E

Cmax of Abemaciclib on day 1 and at steady State (Cycle 2 Day 1) Part A , B, C, D and E was evaluated.

Time frame:
Cycle 1 Day 1 (C1D1) pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; Cycle 2 Day 1 (C2D1) pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib on Day 1 and at Steady State (Cycle 2 Day 1) in Part A , B, C, D and E
nanograms per milliliter (ng/mL)Part A:150 mg Abemaciclib + 500 mg/m^2 PemetrexedPart A: 200 mg Abemaciclib + 500 mg/m^2 PemetrexedPart B: 150 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart C: 150 mg Abemaciclib + 8 mg/kg or 10 mg/kg RamucirumabPart C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day 1Part D: 100 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 100 or 150 or 200 mg LY3023414Part D: 200 mg Abemaciclib + 150 mg LY3023414Part E: 100 mg Abemaciclib + 200 mg PembrolizumabPart E: 150 mg Abemaciclib + 200 mg Pembrolizumab
Day 1114 ± 67.4212 ± 79.880.6 ± 14.7201 ± 71.7140 ± 95.7195 ± 85.886.2 ± 91.1159 ± 74.1225 ± 103125 ± 57.2114 ± 68.8
Steady StateNA ± NA509 ± 40.5NA ± NA417 ± 77.7322 ± 112228 ± 152227 ± 85.1305 ± 55.8—270 ± 47.7240 ± 87.5
SecondaryPharmacokinetics: Maximum Concentration (Cmax) of Pemetrexed at Steady State in Part A

Cmax of pemetrexed at steady state in Part A was evaluated.

Time frame:
C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
Reported as:
Geometric mean · microgram per milliliter (μg/mL)
Pharmacokinetics: Maximum Concentration (Cmax) of Pemetrexed at Steady State in Part A
microgram per milliliter (μg/mL)Part A:150 mg Abemaciclib + 500 mg/m^2 PemetrexedPart A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed
Pharmacokinetics: Maximum Concentration (Cmax) of Pemetrexed at Steady State in Part A98.1 ± 2993.5 ± 30
SecondaryPK: Dose-normalized Maximum Concentration (Cmax) of Active Gemcitabine Metabolite: 2',2'-Difluorodeoxyuridine (dFdU) on Day 1 and at Steady State (Cycle 2 Day 1) in Part B

Cmax of active gemcitabine metabolite (dFdU) on day 1 and at steady state (Cycle 2 Day 1) dose-normalized to 1250 mg/m\^2 in Part B was evaluated.

Time frame:
C1D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
PK: Dose-normalized Maximum Concentration (Cmax) of Active Gemcitabine Metabolite: 2',2'-Difluorodeoxyuridine (dFdU) on Day 1 and at Steady State (Cycle 2 Day 1) in Part B
nanogram per milliliter (ng/mL)Part B: 150 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg or MTD Abemaciclib + 1250 mg/m^2 Gemcitabine
Day 135600 ± 1449600 ± 1241900 ± 21
Steady StateNA ± NA38700 ± 1835800 ± 17
SecondaryPK: Maximum Concentration (Cmax) of Ramucirumab at 1 Hour Post-End-of-Infusion in Part C

Cmax of ramucirumab at 1 hour post-end-of-Infusion in Part C was evaluated.

Time frame:
C1D1 and C2D1: 1 hour post-end-of-infusion
Reported as:
Geometric mean · microgram per milliliter (μg/mL)
PK: Maximum Concentration (Cmax) of Ramucirumab at 1 Hour Post-End-of-Infusion in Part C
microgram per milliliter (μg/mL)Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Day 1Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1
C1D1174 ± 19.6226 ± 10.0193 ± 27.0221 ± 30.6
C2D1221 ± 15.0NA ± NANA ± NA226 ± 32.3
SecondaryPK: Maximum Concentration (Cmax) of LY3023414 in Part D

Cmax of LY3023414 in Part D was evaluated.

Time frame:
C1D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
PK: Maximum Concentration (Cmax) of LY3023414 in Part D
nanograms per milliliter (ng/mL)Part D: 100 or 150 mg Abemaciclib + 100 mg LY3023414Part D: 150 or 200 mg Abemaciclib + 150 mg LY3023414Part D: 150 mg Abemaciclib + 200 mg LY3023414
Day 1298 ± 104454 ± 81578 ± 119
Steady State438 ± 63491 ± 52NA ± NA
SecondaryPK: Area Under the Concentration Curve (AUC) of Abemaciclib in Part A, B, C, D and E

Area under the concentration time curve from zero to 8 hours AUC(0-8h) of abemaciclib in Part A, B, C, D and E was evaluated.

Time frame:
C1D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
Reported as:
Geometric mean · nanogram*hour/mL (ng*h/mL)
PK: Area Under the Concentration Curve (AUC) of Abemaciclib in Part A, B, C, D and E
nanogram*hour/mL (ng*h/mL)Part A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 PemetrexedPart A: 200 mg Abemaciclib + 500 mg/m^2 PemetrexedPart B: 150 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart C: 150 mg Abemaciclib + 8 mg/kg or 10 mg/kg RamucirumabPart C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1Part D: 100 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 100 or 150 or 200 mg LY3023414Part D: 200 mg Abemaciclib + 150 mg LY3023414Part E: 100 mg Abemaciclib + 200 mg PembrolizumabPart E: 150 mg Abemaciclib + 200 mg Pembrolizumab
Day 1533 ± 69.6979 ± 77.5393 ± 31.0886 ± 53.4797 ± 69.01030 ± 127394 ± 71.7719 ± 77.3967 ± 139NA ± NA518 ± 21.6
Steady StateNA ± NA3710 ± 41.1NA ± NA2690 ± 53.41720 ± 1191840 ± 115NA ± NA1550 ± 83.7——1400 ± 184
SecondaryPK: Area Under the Concentration Curve (AUC) of Pemetrexed at Steady State in Part A

Area under the plasma concentration versus time curve from time zero to infinity (AUC\[0-∞\]) of Pemetrexed in Part A was evaluated.

Time frame:
C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
Reported as:
Geometric mean · microgram*hour per milliliter (μg*hr/mL)
PK: Area Under the Concentration Curve (AUC) of Pemetrexed at Steady State in Part A
microgram*hour per milliliter (μg*hr/mL)Part A:150 mg Abemaciclib + 500 mg/m^2 PemetrexedPart A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed
PK: Area Under the Concentration Curve (AUC) of Pemetrexed at Steady State in Part A201 ± 30198 ± 32
SecondaryPK: Area Under the Concentration Curve (AUC) of Active Gemcitabine Metabolite: 2',2'-Difluorodeoxyuridine (dFdU) on Day 1 and at Steady State (Cycle 2 Day 1) in Part B

Area under the plasma concentration time curve from time zero to 12 hours (AUC\[0-12h\]) of active gemcitabine metabolite (dFdU) in Part B was evaluated

Time frame:
C1D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
Reported as:
Geometric mean · nanogram*hour/mL (ng*h/mL)
PK: Area Under the Concentration Curve (AUC) of Active Gemcitabine Metabolite: 2',2'-Difluorodeoxyuridine (dFdU) on Day 1 and at Steady State (Cycle 2 Day 1) in Part B
nanogram*hour/mL (ng*h/mL)Part B: 150 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine200 mg or MTD Abemaciclib + 1250 mg/m^2 Gemcitabine
Day 1175000 ± 16246000 ± 29198000 ± 26
Steady StateNA ± NA208000 ± 20210000 ± 23
SecondaryPK: Area Under the Concentration Curve (AUC) of LY3023414 in Part D

Area under the plasma concentration versus time curve from time zero to infinity (AUC) of LY3023414 in Part D was evaluated. For Day 1, AUC is defined as AUC from time zero to infinity (AUC\[0-∞\]), for steady state, AUC is defined as AUC from time zero to the end of the dosing interval, tau (AUC\[0-tau \])

Time frame:
C1D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
Reported as:
Geometric mean · nanogram*hour/mL (ng*h/mL)
PK: Area Under the Concentration Curve (AUC) of LY3023414 in Part D
nanogram*hour/mL (ng*h/mL)Part D: 100 or 150 mg Abemaciclib + 100 mg LY3023414Part D: 150 or 200 mg Abemaciclib + 150 mg LY3023414Part D: 150 mg Abemaciclib + 200 mg LY3023414
Day 11005 ± 631751 ± 563809 ± 95
Steady State1303 ± 641293 ± 49NA ± NA

Adverse events

Collected over Up to 4 years and 1 Month. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A:150 mg Abemaciclib + 500 mg/m^2 Pemetrexed2/8 (25%)4/8 (50%)8/8 (100%)
Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed1/15 (6.7%)8/15 (53.3%)15/15 (100%)
Part B:150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine6/21 (28.6%)10/21 (47.6%)21/21 (100%)
Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Day12/4 (50%)3/4 (75%)4/4 (100%)
Part C: 200 mg Abemaciclib + 10 mg/kg Ramucirumab Day14/19 (21.1%)12/19 (63.2%)19/19 (100%)
Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 81/12 (8.3%)3/12 (25%)12/12 (100%)
Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 81/4 (25%)3/4 (75%)4/4 (100%)
Part D: 100 mg Abemaciclib + 100 mg LY30234140/3 (0%)1/3 (33.3%)3/3 (100%)
Part D: 150 mg Abemaciclib + 100 mg LY30234141/9 (11.1%)2/9 (22.2%)8/9 (88.9%)
Part D: 150 mg Abemaciclib + 150 mg LY30234140/10 (0%)3/10 (30%)10/10 (100%)
Part D: 200 mg Abemaciclib + 150 mg LY30234141/6 (16.7%)0/6 (0%)5/6 (83.3%)
Part D: 150 mg Abemaciclib + 200 mg LY30234141/8 (12.5%)4/8 (50%)8/8 (100%)
Part E: 100 mg Abemaciclib + 200 mg Pembrolizumab0/3 (0%)0/3 (0%)3/3 (100%)
Part E: 150 mg Abemaciclib + 200 mg Pembrolizumab2/17 (11.8%)9/17 (52.9%)16/17 (94.1%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
EventPart A:150 mg Abemaciclib + 500 mg/m^2 PemetrexedPart A: 200 mg Abemaciclib + 500 mg/m^2 PemetrexedPart B:150 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Day1Part C: 200 mg Abemaciclib + 10 mg/kg Ramucirumab Day1Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8Part D: 100 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 150 mg LY3023414Part D: 200 mg Abemaciclib + 150 mg LY3023414Part D: 150 mg Abemaciclib + 200 mg LY3023414Part E: 100 mg Abemaciclib + 200 mg PembrolizumabPart E: 150 mg Abemaciclib + 200 mg Pembrolizumab
Coronary artery diseaseCardiac disorders0/80/150/30/210/40/190/120/41/30/90/100/60/80/30/17
PancreatitisGastrointestinal disorders0/80/150/30/210/40/190/120/41/30/90/100/60/80/30/17
PneumoniaInfections and infestations0/81/150/33/211/41/190/121/41/31/90/100/60/80/30/17
Renal failureRenal and urinary disorders0/81/150/30/210/41/190/120/41/30/91/100/60/80/30/17
DyspnoeaRespiratory, thoracic and mediastinal disorders0/81/151/31/210/40/191/120/40/30/90/100/60/80/30/17
Cardiac arrestCardiac disorders0/80/150/30/211/40/190/120/40/30/90/100/60/80/30/17
Myocardial infarctionCardiac disorders0/80/150/30/210/40/190/121/40/30/90/100/60/80/30/17
Septic shockInfections and infestations0/80/150/30/210/41/190/121/40/30/90/100/60/80/30/17
Myocardial strainInvestigations0/80/150/30/211/40/190/120/40/30/90/100/60/80/30/17
Subclavian artery thrombosisVascular disorders0/80/150/30/210/40/190/121/40/30/90/100/60/80/30/17
Most frequent other events
Showing 10 of 269
Most frequent other events
EventPart A:150 mg Abemaciclib + 500 mg/m^2 PemetrexedPart A: 200 mg Abemaciclib + 500 mg/m^2 PemetrexedPart B:150 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Day1Part C: 200 mg Abemaciclib + 10 mg/kg Ramucirumab Day1Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8Part D: 100 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 150 mg LY3023414Part D: 200 mg Abemaciclib + 150 mg LY3023414Part D: 150 mg Abemaciclib + 200 mg LY3023414Part E: 100 mg Abemaciclib + 200 mg PembrolizumabPart E: 150 mg Abemaciclib + 200 mg Pembrolizumab
NauseaGastrointestinal disorders5/86/153/313/211/412/196/122/42/35/96/103/64/80/37/17
FatigueGeneral disorders5/812/152/317/212/412/195/120/42/34/94/102/62/83/312/17
DiarrhoeaGastrointestinal disorders4/814/151/313/212/414/1910/122/42/36/99/101/66/81/310/17
AnaemiaBlood and lymphatic system disorders6/812/151/310/210/45/192/120/42/33/92/100/63/82/36/17
VomitingGastrointestinal disorders3/84/150/38/211/411/193/121/42/34/97/102/66/80/34/17
AstheniaGeneral disorders0/81/150/32/210/40/194/123/40/30/91/101/62/80/33/17
Decreased appetiteMetabolism and nutrition disorders4/89/150/39/211/46/196/123/41/32/93/102/65/81/39/17
Lung infectionInfections and infestations0/80/152/31/210/40/190/120/40/30/90/100/60/80/30/17
Upper respiratory tract infectionInfections and infestations0/80/151/30/210/41/190/120/40/30/90/100/60/82/35/17
Neutrophil count decreasedInvestigations5/84/152/39/210/43/191/121/42/30/90/100/60/80/30/17

Baseline characteristics

All randomized participants who received at least one dose of study drug in Part A, B, C, D and E.

Age, Continuous
Age, Continuous(years)Part A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 PemetrexedPart A: 200 mg Abemaciclib + 500 mg/m^2 PemetrexedPart B: 150 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart C:150 mg Abemaciclib+10mg/kg Ramucirumab Day1Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8Part D: 100 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 150 mg LY3023414Part D: 200 mg Abemaciclib + 150 mg LY3023414Part D: 150 mg Abemaciclib + 200 mg LY3023414Part E: 100 mg Abemaciclib + 200 mg PembrolizumabPart E: 150 mg Abemaciclib + 200 mg PembrolizumabTotal
Mean63.88 ± 7.6162.53 ± 11.1955.00 ± 8.6663.14 ± 10.0761.25 ± 14.2466.11 ± 9.3163.75 ± 6.7767.75 ± 4.9267.00 ± 9.5457.56 ± 8.2664.00 ± 8.4165.50 ± 7.4860.38 ± 10.2067.33 ± 3.5159.76 ± 9.9462.89 ± 9.30
Sex: Female, Male
Sex: Female, Male(Participants)Part A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 PemetrexedPart A: 200 mg Abemaciclib + 500 mg/m^2 PemetrexedPart B: 150 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart C:150 mg Abemaciclib+10mg/kg Ramucirumab Day1Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8Part D: 100 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 150 mg LY3023414Part D: 200 mg Abemaciclib + 150 mg LY3023414Part D: 150 mg Abemaciclib + 200 mg LY3023414Part E: 100 mg Abemaciclib + 200 mg PembrolizumabPart E: 150 mg Abemaciclib + 200 mg PembrolizumabTotal
Female45011210401532511063
Male4103102984247432779
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 PemetrexedPart A: 200 mg Abemaciclib + 500 mg/m^2 PemetrexedPart B: 150 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart C:150 mg Abemaciclib+10mg/kg Ramucirumab Day1Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8Part D: 100 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 150 mg LY3023414Part D: 200 mg Abemaciclib + 150 mg LY3023414Part D: 150 mg Abemaciclib + 200 mg LY3023414Part E: 100 mg Abemaciclib + 200 mg PembrolizumabPart E: 150 mg Abemaciclib + 200 mg PembrolizumabTotal
Hispanic or Latino0111011000011007
Not Hispanic or Latino813220417114391057317133
Unknown or Not Reported0100010000000002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 PemetrexedPart A: 200 mg Abemaciclib + 500 mg/m^2 PemetrexedPart B: 150 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart C:150 mg Abemaciclib+10mg/kg Ramucirumab Day1Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8Part D: 100 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 150 mg LY3023414Part D: 200 mg Abemaciclib + 150 mg LY3023414Part D: 150 mg Abemaciclib + 200 mg LY3023414Part E: 100 mg Abemaciclib + 200 mg PembrolizumabPart E: 150 mg Abemaciclib + 200 mg PembrolizumabTotal
American Indian or Alaska Native0002000000000002
Asian0102010000011017
Native Hawaiian or Other Pacific Islander0000000000000000
Black or African American0101000012000005
White813316418124271057316128
More than one race0000000000000000
Unknown or Not Reported0000000000000000
Region of Enrollment
Region of Enrollment(Participants)Part A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 PemetrexedPart A: 200 mg Abemaciclib + 500 mg/m^2 PemetrexedPart B: 150 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart B: 200 mg Abemaciclib + 1250 mg/m^2 GemcitabinePart C:150 mg Abemaciclib+10mg/kg Ramucirumab Day1Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8Part D: 100 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 100 mg LY3023414Part D: 150 mg Abemaciclib + 150 mg LY3023414Part D: 200 mg Abemaciclib + 150 mg LY3023414Part D: 150 mg Abemaciclib + 200 mg LY3023414Part E: 100 mg Abemaciclib + 200 mg PembrolizumabPart E: 150 mg Abemaciclib + 200 mg PembrolizumabTotal
United States68216415613910680397
Spain271504630000031445
08

Study locations

11 sites
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • UCLA Department of Medicine-Hematology/Oncology
    Los Angeles, California 90095, United States
  • University of California, Davis - Health Systems
    Sacramento, California 95817, United States
  • Indiana Cancer Pavilion
    Indianapolis, Indiana 46202, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • University of New Mexico Cancer Center
    Albuquerque, New Mexico 87102, United States
  • Carolinas Medical Center
    Charlotte, North Carolina 28204, United States
  • The West Clinic
    Germantown, Tennessee 38138, United States
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Majadahonda, 28222, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sevilla, 41013, Spain
09

References and documents

Publications

  • Kim ES, Kelly K, Paz-Ares LG, Garrido P, Jalal S, Mahadevan D, Gutierrez M, Provencio M, Schaefer E, Shaheen M, Johnston EL, Turner PK, Kambhampati SRP, Beckmann R, Hossain A, John WJ, Goldman JW. Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. Clin Cancer Res. 2018 Nov 15;24(22):5543-5551. doi: 10.1158/1078-0432.CCR-18-0651. Epub 2018 Aug 6. PubMed 30082474 ↗
  • Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, Torres R, Ajamie RT, Wishart GN, Flack RS, Neubauer BL, Young J, Chan EM, Iversen P, Cronier D, Kreklau E, de Dios A. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014 Oct;32(5):825-37. doi: 10.1007/s10637-014-0120-7. Epub 2014 Jun 13. PubMed 24919854 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in May 2018, 49 months.

Results were first posted in Sep 2020, 2 years 4 months after primary completion.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 49 months is close to that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2014
First posted
Mar 6, 2014
StartActual
Mar 28, 2014
Primary completionActual
May 2, 2018
CompletionActual
Aug 29, 2019
Results first posted
Sep 11, 2020
Last update
Sep 11, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02079636
Responsible party
Sponsor
First posted
Mar 6, 2014
Start date
Mar 28, 2014
Primary completion
May 2, 2018
Completion
Aug 29, 2019
Results posted
Sep 11, 2020
Last update
Sep 11, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abemaciclib · Ramucirumab · LY3023414

Start the discussion